| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers Z > Headlines for Ziopharm Oncology, Inc. > News item |
Ziopharm says it will announce details of third clinical program this year
By Jennifer Lanning Drey
Eugene, Ore., Sept. 13 - Ziopharm Oncology, Inc. plans to in-license and announce details of a third developmental program, ZIO-301, before the end of 2006, Jonathon J. Lewis, the company's chief executive officer, told investors Wednesday at the ThinkEquity growth conference.
In addition, the company expects to begin pivotal clinical trials within its two current oncology programs, ZIO-101 and ZIO-201, in 2007, Lewis said.
The pivotal trials will be funded by proceeds from the company's $37 million stock offering in May.
ZIO-101, an organic arsenic drug, is being studied in a phase 1/ 2 clinical trial for myeloma, with additional trials for solid tumors also planned, Lewis said.
"Myeloma will be the lead program but we will continue to expand phase 2 programs in hematologic cancers and in solid tumors," he said.
Early data have suggested ZIO-101 might be active in cancers where arsenic trioxide is ineffective or too toxic.
The company is also pre-clinically exploring an orally dosed version of the drug, which it expects to be in the clinic in the first half of 2007, Lewis said.
In addition, he said ZIO-201 (isophosphoramide mustard-lysine), the active metabolite of ifosfamide, is expected to move into pivotal trials in late 2007 for sarcoma.
The drug candidate could provide a market opportunity of $400 million per year for the company, he said.
Ziopharm is also planning trials to study the drug as a treatment for lymphoma and pediatric tumors, he added.
Ziopharm, a New York biopharmaceutical company, reported the data at the annual meeting of the American Society of Clinical Oncology in Atlanta.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.